Exploratory Study of the Relevance of a Blood Test in the Management of Patients in the Co
Colorectal cancer (CRC) is the third most common cancer in men and the second in women with an incidence of 43,350 new cases in 2018. This incidence is increasing every year. Early detection is crucial in this pathology. In France, free screening is organized by health insurance for people aged 50 to 74 years. This scr
| Condition(s) | Colorectal Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Colorectal cancer (CRC) is the third most common cancer in men and the second in women with an incidence of 43,350 new cases in 2018. This incidence is increasing every year. Early detection is crucial in this pathology. In France, free screening is organized by health insurance for people aged 50 to 74 years. This screening is based on an immunological test (FIT: Fecal Immunological test), which aims to detect the presence of blood in the stool. In fact, some polyps or cancers cause bleeding that is often minimal and therefore difficult or even impossible to detect with the naked eye. If this test is positive, a colonoscopy is done to check whether or not abnormalities are present in the colon or rectum. Performed under anesthesia, this examination can detect the possible presence of poly |
| Who can participate | Inclusion Criteria: * Patients aged more than18 years * Cohort A : patients with suspected colorectal cancer following a positive immunological test during screening (presence of blood detected in the stool) or with gross bleeding OR Cohort B : patients who have already performed colonoscopy (on symptoms, or because of family history, or other ...), for whom the diagnosis of adenocarcinoma was identified by pathology prior to surgery, candidates for surgery on their colorectal tumor * Signed and dated informed consent * Patient affiliated to or beneficiary of French social security system. Exclusion Criteria: * Vulnerable persons according to the law (minors, adults under protection, persons deprived of liberty ...) * Not ability to comply with the study protocol, in the Investigator's jud |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Centre Hospitalier Universitaire de Besancon |
| Locations | Besançon, France; Montbéliard, France; Vesoul, France |
| Start date | 2021-03-30 |
| NCT ID | NCT04767568 |
| Official listing | https://clinicaltrials.gov/study/NCT04767568 |